Ovarian cancers, particularly high-grade serous ovarian carcinoma, exhibit significant heterogeneity at both the molecular and cellular levels, which complicates the identification of a universal set of fibroblast activation-specific (FAS) surface markers. This evidence concerns the gene FAS and ovarian carcinoma.